Exploring the experience of the physicians regarding COVID-19, its complications and management

Background: COVID-19 infection is a disease that remains the main concern globally due to high admissions and fatality rates among patients. Clinical manifestation and choice of treatment are various. Therefore, this study was developed to explore the physicians' perceptions in this regard in a semi-governmental hospital in Sharjah. Aims and Objectives: The objective of this research is to (1) to outline physicians' descriptions of the clinical presentation of COVID-19, (2) to explore the physicians' perceptions regarding the different aspects of COVID-19 and its complications, and (3) explore the physicians' experiences regarding the treatment of COVID-19 cases. Material(s) and Method(s): A descriptive qualitative design was approached. A semi-structured interview guide was developed, validated and used for data collection. Ten in-depth individual interviews with physicians were conducted. Interviews were recorded, transcribed, and thematically analyzed. Result(s): After analysis, three main themes with their sub-themes emerged to describe physicians' experience regarding COVID-19's clinical presentation, complications, and management. Sub-themes cleared-up COVID-19's signs, symptoms, and risk factors along with admission's requirements. Furthermore, it showed COVID-19's complication in main organs. Moreover, COVID-19's treatment was clarified for both home-quarantine and admitted patients along with instructions for discharged patients. Conclusion(s): Cases varied in severity and classified from asymptomatic to severe. It showed the requirements for hospitalization and risk factors associated with severity. The management of COVID-19 disease followed by MOHAP protocol and provided adequate outcomes from physicians. Vaccination was one of physicians' recommendations.Copyright © 2023 Doaa Kamal AlKhalidi, et al.

Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs).

The causative agent of coronavirus disease-2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enters the host cells via an angiotensin-converting enzyme 2 (ACE2)-mediated endocytosis-dependent manner. Because ACE2 is highly expressed in the heart, SARS-CoV-2 can severely infect heart tissue and arteries, causing acute and chronic damage to the cardiovascular system. Therefore, special attention should be paid to finding appropriate agents to protect this vital system during COVID-19 treatment. Papaverine is a unique vasodilator alkaloid that is clinically used in the treatment of vasospasm. Interestingly, this compound has potent and direct effects on a wide range of viruses, and could also prevent viral exploitation mechanisms of the host cell facilities by inhibiting some cellular signaling pathways such as p38 MAPK. This pathway was recently introduced as a promising target for the treatment of COVID-19. Papaverine also has anti-inflammatory effects which is useful in combating the hyper-inflammatory phase of the COVID-19. Unlike some medications that have severe dosage-restrictions in the treatment of COVID-19 due to cardiac side effects, papaverine is recommended for use in many heart disorders. The ability of papaverine to treat COVID-19 has become more promising when the results of some extensive screenings showed the strong ability of this compound to inhibit the cytopathic effects of SARS-CoV-2 with EC50 of 1.1 µM. Having several therapeutic effects along with desired safety profile raises this hypothesis that papaverine could be a promising compound for the suppression of SARS-CoV-2 and prevention of ischemia/vasoconstriction-related complications in COVID-19 disease, especially in patients with underlying cardiovascular diseases (CVDs).

An Insight into Recent Advances on Platelet Function in Health and Disease.

Platelets play a variety of roles in vascular biology and are best recognized as primary hemostasis and thrombosis mediators. Platelets have a large number of receptors and secretory molecules that are required for platelet functionality. Upon activation, platelets release multiple substances that have the ability to influence both physiological and pathophysiological processes including inflammation, tissue regeneration and repair, cancer progression, and spreading. The involvement of platelets in the progression and seriousness of a variety of disorders other than thrombosis is still being discovered, especially in the areas of inflammation and the immunological response. This review represents an integrated summary of recent advances on the function of platelets in pathophysiology that connects hemostasis, inflammation, and immunological response in health and disease and suggests that antiplatelet treatment might be used for more than only thrombosis.

The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It.

Coronavirus disease is caused by the SARS-CoV-2 virus. The virus first appeared in Wuhan (China) in December 2019 and has spread globally. Till now, it affected 269 million people with 5.3 million deaths in 224 countries and territories. With the emergence of variants like Omicron, the COVID-19 cases grew exponentially, with thousands of deaths. The general symptoms of COVID-19 include fever, sore throat, cough, lung infections, and, in severe cases, acute respiratory distress syndrome, sepsis, and death. SARS-CoV-2 predominantly affects the lung, but it can also affect other organs such as the brain, heart, and gastrointestinal system. It is observed that 75 % of hospitalized COVID-19 patients have at least one COVID-19 associated comorbidity. The most common reported comorbidities are hypertension, NDs, diabetes, cancer, endothelial dysfunction, and CVDs. Moreover, older and pre-existing polypharmacy patients have worsened COVID-19 associated complications. SARS-CoV-2 also results in the hypercoagulability issues like gangrene, stroke, pulmonary embolism, and other associated complications. This review aims to provide the latest information on the impact of the COVID-19 on pre-existing comorbidities such as CVDs, NDs, COPD, and other complications. This review will help us to understand the current scenario of COVID-19 and comorbidities; thus, it will play an important role in the management and decision-making efforts to tackle such complications.

From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19.

In the past year, researchers have focused their attention on developing new strategies for understanding how the coronavirus affects human health and developing novel biomaterials to help patients with cardiovascular disease, which greatly increases the risk of complications from the virus. Natural biopolymers have been investigated, and it has been proven that alginate-based materials have important features. This review presents an overview of alginate-based materials used for developing innovative biomaterial platforms for biomedical applications to mitigate the effects of the coronavirus. As presented in this review, COVID-19 affects the cardiovascular system, not only the lungs. The first part of the review presents an introduction to cardiovascular diseases and describes how they have become an important problem worldwide. In the second part of the review, the origin and unique properties of the alginate biopolymer are presented. Among the properties of alginate, the most important are its biocompatibility, biodegradability, low cost, nontoxicity, unique structure, and interesting features after chemical modification. The third section of the review illustrates some of the functions of alginate in biomedical, pharmaceutical, and drug delivery applications. Researchers are using alginate to develop new devices and materials for repairing heart tissues that have been damaged by the coronavirus. Further, insights regarding how cardiovascular disease affects COVID-19 patients are also discussed. Finally, we conclude the review by presenting a summary of the impacts of COVID-19 on cardiovascular patients, their implications, and several hypothetical alginate-based treatments for infected patients.

Development of Smart Healthcare Tracker through Internet of Things

According to the World Health Organization, there are approximately 17.9 million people in the world who will die under the cause of Cardiovascular diseases (CVDs) in 2019. Heart and Brain are both related to Cardiovascular diseases. Even if the patients do not pass away due to the disease, the post-effect of this illness burdens the patients and their families. Also, the outbreak of COVID-19 makes the patients take a risk of undergoing rehabilitation in the hospital. Thus, a smart healthcare solution which is a Smart Healthcare Tracker through the Internet of Things is designed. The system consists of an EMG sensor, accelerometer, gyroscope, and heart rate/pulse oximeter connected to ESP 32 with an interface of NodeMCU to study the patients' health condition for arms and legs strength by sending the data to the caregivers or physicians. The project aimed to obtain a consistent and accurate reading for each of the features for arms and legs strength analysis and sleeping disturbance analysis. The BLYNK app is also applied to the project design as a platform to display the analysis result to the caregivers/physicians on the gadgets at any time and anywhere. The prototype has been constructed and the data collection is built successfully. The prototype is trusted to obtain accurate and consistent results and can provide a sustainable way for the rehabilitation to indicate the health condition and the recovery stage of the patients. © 2021 IEEE.

COV-ECGNET: COVID-19 detection using ECG trace images with deep convolutional neural network.

The reliable and rapid identification of the COVID-19 has become crucial to prevent the rapid spread of the disease, ease lockdown restrictions and reduce pressure on public health infrastructures. Recently, several methods and techniques have been proposed to detect the SARS-CoV-2 virus using different images and data. However, this is the first study that will explore the possibility of using deep convolutional neural network (CNN) models to detect COVID-19 from electrocardiogram (ECG) trace images. In this work, COVID-19 and other cardiovascular diseases (CVDs) were detected using deep-learning techniques. A public dataset of ECG images consisting of 1937 images from five distinct categories, such as normal, COVID-19, myocardial infarction (MI), abnormal heartbeat (AHB), and recovered myocardial infarction (RMI) were used in this study. Six different deep CNN models (ResNet18, ResNet50, ResNet101, InceptionV3, DenseNet201, and MobileNetv2) were used to investigate three different classification schemes: (i) two-class classification (normal vs COVID-19); (ii) three-class classification (normal, COVID-19, and other CVDs), and finally, (iii) five-class classification (normal, COVID-19, MI, AHB, and RMI). For two-class and three-class classification, Densenet201 outperforms other networks with an accuracy of 99.1%, and 97.36%, respectively; while for the five-class classification, InceptionV3 outperforms others with an accuracy of 97.83%. ScoreCAM visualization confirms that the networks are learning from the relevant area of the trace images. Since the proposed method uses ECG trace images which can be captured by smartphones and are readily available facilities in low-resources countries, this study will help in faster computer-aided diagnosis of COVID-19 and other cardiac abnormalities.

Cardiovascular manifestations in COVID-19 patients: A systematic review and meta-analysis.

Since December 2019, the COVID-19 pandemic has affected the global population, and one of the major causes of mortality in infected patients is cardiovascular diseases (CVDs).For this systematic review and meta-analysis, we systematically searched Google Scholar, Scopus, PubMed, Web of Science, and Cochrane databases for all articles published by April 2, 2020. Observational studies (cohort and cross-sectional designs) were included in this meta-analysis if they reported at least one of the related cardiovascular symptoms or laboratory findings in COVID-19 patients. Furthermore, we did not use any language, age, diagnostic COVID-19 criteria, and hospitalization criteria restrictions. The following keywords alone or in combination with OR and AND operators were used for searching the literature: "Wuhan coronavirus", "COVID-19", "coronavirus disease 2019", "SARS-CoV-2", "2019 novel coronavirus" "cardiovascular disease", "CVD", "hypertension", "systolic pressure", "dyspnea", "hemoptysis", and "arrhythmia". Study characteristics, exposure history, laboratory findings, clinical manifestations, and comorbidities were extracted from the retrieved articles. Sixteen studies were selected which involved 4754 patients, including 2103 female and 2639 male patients. Among clinical cardiac manifestations, chest pain and arrhythmia were found to have the highest incidence proportion. In addition, elevated lactate dehydrogenase (LDH) and D-dimer levels were the most common cardiovascular laboratory findings. Finally, hypertension, chronic heart failure, and coronary heart disease were the most frequently reported comorbidities. The findings suggest that COVID-19 can cause various cardiovascular symptoms and laboratory findings. It is also worth noting that cardiovascular comorbidities like hypertension have a notable prevalence among COVID-19 patients.

COVID-19 lockdown may increase cardiovascular disease risk factors.

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and was declared a worldwide pandemic by the World Health Organization (WHO) on 11 March 2020 which is leading to significant morbidity and mortality. In compliance with WHO recommendation of movement restrictions, many countries have imposed compulsory self-quarantine and restricted movements of their citizenries (lockdown/sit at home) and closure of businesses and borders as preventive measures to the fast-spreading virus. Consequently, this decision has made the emergence of behaviors that are detrimental to cardiovascular diseases (CVDs) which are the leading cause of the global mortality rate. MAIN BODY: The increase in sedentary lifestyles, alcohol consumption, and substance abuse during COVID-19 pandemic lockdown as a result of personal restrictions in COVID-19 lockdown is linked with the risk of death from chronic diseases such as cardiovascular diseases (CVDs). CONCLUSION: The lockdown has increased risk factors of CVDs, and as such, there might be an increase in the number of non-communicable disease (NCD)-related mortality rate. The effect does not end during the period of coronavirus pandemic but even after the pandemic.

Cardiovascular Diseases (CVDs) in COVID-19 Pandemic Era.

INTRODUCTION: COVID-19 is the disease caused by an infection of the SARS-CoV-2 virus, previously known as 2019 Novel Coronavirus (2019-nCoV) respiratory disease. World Health Organization (WHO) declared the official name as COVID-19 in February 2020 and in 11th March 2020 declared COVID-19 as Global Pandemic. In June 6th 2020, over 7 million cases registered in the world, recovered 3.4 million and death over 402.000. AIM: The aim of this study is to retreive published papers about COVID-19 infection deposited in PubMed data base and analyzed current results of investigations regarding morbidity and mortality rates as consequences of COVID-19 infection and opinions of experts about treatment of afected patients with COVID-19 who have Cardiovascular diseases (CVDs). METHODS: It's used method of descriptive analysis of the published papers with described studies about Corona virus connected with CVDs. RESULTS: After searching current scientific literature (on PubMed till today is deposited more than 1.000 papers about COVID-19 with consequences in almost every medical disciplines), we have acknowledged that till today not any Evidence Based Medicine (EBM) study in the world. Also, there are no unique proposed ways of treatments and drugs to protect patients, especially people over 65 years old, who are very risk group to be affected with COVID-19, including patients with CVDs. Vaccine against COVID-19 is already produced and being in phases of testing in praxis in treatment of COVID-19 at affected patients, but the opinions of experts and common people whole over the world about vaccination are full of controversis. CONCLUSION: Frequent hand washing, avoiding crowds and contact with sick people, and cleaning and disinfecting frequently touched surfaces can help prevent coronavirus infections are the main proposal of WHO experts in current Guidelines, artefacts stored on a web site. Those preventive measures at least can help to everybody, including also the patients who have evidenced CVDs in their histories of illness. Authors analyzed most important dilemmas about all aspects of CVDs, including etipathogenesis, treatment with current drugs and use of potential discovered vaccines against COVID-19 infection, described in scientific papers deposited in PubMed data base.

Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium.

Patients with cardiovascular disease and diabetes are at potentially higher risk of infection and fatality due to COVID-19. Given the social and economic costs associated with disability due to these conditions, it is imperative that specific considerations for clinical management of these patients be observed. Moreover, the reorganization of health services around the pandemic response further exacerbates the growing crisis around limited access, treatment compliance, acute medical needs, and mental health of patients in this specific subgroup. Existing recommendations and guidelines emanating from respective bodies have addressed some of the pressure points; however, there are variations and limitations vis a vis patient with multiple comorbidities such as obesity. This article will pull together a comprehensive assessment of the association of cardiovascular disease, diabetes, obesity and COVID-19, its impact on the health systems and how best health systems can respond to mitigate current challenges and future needs. We anticipate that in the context of this pandemic, the cardiovascular disease and diabetes patients need a targeted strategy to ensure the harm to this group does not translate to huge costs to society and to the economy. Finally, we propose a triage and management protocol for patients with cardiovascular disease and diabetes in the COVID-19 settings to minimize harm to patients, health systems and healthcare workers alike.